FDA Investigator Nicholas F Lyons

Nicholas F Lyons has inspections in 3 countries as of 16 Oct 2023. Nicholas F Lyons has collaborated with a combinined 3458 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
68
Last Inspection Date:
16 Oct 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America, Canada
Co-Investigator(s):
Aditi S Thakur, Alan M Roberts, Alicia M Mozzachio, Amanda Dinaro, Amanda E Lewin, PhD, Amanda S Zorn, Amy Devlin, PhD, Anders W Evenson, Ann Marie Montemurro, Ann Marie Schofield, Anna Flynn, Arsen Karapetyan, Ashley L Reiber, Aurora Miha Trifanov, Barbara D Wright, Barry Cherney, PhD, Brenda W Uratani, PhD, Brian D Nicholson, Brian P Emanuel, Brittani N Franklin, Bruce H Mccullough, Bryan L Mcguckin, Camerson E Moore, Carla J Lundi, Carlyn L Ray, Carrie Ann Plucinski, Chad E Schmear, Charanjeet Jassal, Charisse K Green, Charles L Zhou, Charlie P Booker, Chase S Baldwin, Chiang Syin, PhD, Christina A Miller, Christina V Santos, Christopher D Leach, Clotia Cabbey Mensah, Constantin Y Philopoulos, Daniel B Arrecis, Daniel C Kearns, Daniel J Brown, Daniel Kearns, Dariusz Galezowski, Darrell E Luedtke, David Perkins, Debra Boyd Seale, Debra I Love, Debra L Boyd Seale, Denarvis C Mendenhall, Diane L Raccasi, Donna A Katz, Donna K Speer, Dr. Guang Gao, PhD, Eileen A Liu, Elizabeth L Holmes, Elliot P Cowam, PhD, Enrico Joset Mangahis, Enrico Mangahis, Eric M Mueller, PharmD, Eric S Pittman, Frank Wackes, Freed A Sharif, Gene D Arcy, Harperd, Helen B Ricalde, Humera Khan, Humera T Khan, Israel Santiago, OCM, James A Jagon, James L Finn, James W Plucinski, Jan B Welch, Jan Welch, Janae D Price, Jason F Chancey, Jayne E Holcomb, Jeanne M Morris, Jennifer C Adams, Jennifer C Johnson, Jesse A Vazquez, Joan A Loreng, Jocelyn C Turner, John E Verbeten, Jonathan G Swoboda, Joseph A Morkunas, Joseph D Cooper, Joshua M Adams, Julie D Bringger, Justin A Boyd, Karen Emasley Joseph, Karen Emaslwey Joseph, Karen M Cooper, Katherine Szestypalow, Kathleen B Swat, Kimberly Lewandowski Walker, Kujtim Sadiku, Lagurta M Mayher, Lakisha M Williams, Larry F Hallberg, Latoya A Griffith, Lauren A Crivellone, Laurie A Haxel, LCDR Mark A Jimenez, RN, Lequita M Mayhew, Li Hongpaul Yeh, PhD, Linda F Murphy, Lindsey S Fleischman, Lisa C Lewis, Lisa Hayka, Lisa Hornback, Lisa M Bellows, Lisa M Feola, Lorelei S Jarrell, Margaret M Annes, Margaret Mtorres Vazquez, Margaret Torres Vazquez, Marisa E Stock, Mark I Kaspar, Mark R Mcclain, Martha T Olone, Martin K Yan, PhD, Martin R Vowell, Matthew J Sienko, Maureen C Melvin, Michael D Robinson, Michael Y Philopoulos, Michele L Glendenning, Micmarie Ramos, Mihaly S Ligmond, Milva E Melendez, Milva Emelendez Perales, Nancy J Lucas, Nibin Varghese, MS, Nicholas P Diorio, Nicole J Clausen, Nicole K Trudel, Nicole S Williams, Norman K Starks, Norman L Brown, Norman Wong, Omotunde O Osunsanmi, Pablo Alcantara, Patricia A Mcilroy, Patrick E Gainer, Paul A Bonneau, Paula A Trost, Paula P Demichael, Peng Zhou, Peterson, Phung Thien Nguyen, Prabhu P Raju, Rafael Padilla, Ralph A Erickson, Rebecca K Olin, Robert D Tollefsen, Robert L Stevenson, Roberta W Cunningham, Rona Leblanc, PhD, Rosemary A Sexton, Russ R Rivy, Russell K Riley, Ryan Gibson, Sandra A Boyd, Sarah B Tanksley, Sarah E Rhoades, Shana L Williams, Shannon A Dinardo, Sharon K Thoma, PharmD, State Agency, Stefen D Mcmillan, Stephanie A Wright, Stephen D Eich, Steven M Weinman, Sullan, Susan A Zullo, PhD, Susan M Jackson, Susan P Bruederle, Susan W Ciani, Tamara Brey, Tara R Gooen, Thomas W Nojek, Timothy Brennan, Todd M Stankewicz, Truong Xuan Nguyen (Andy), Vaishali J Patel, Wayne E Seifert, Wendy G Tan, PhD, William D Sherman, William G Nelson, William R Weissinger, Xikui Chen (nmi), PhD, Yiying E Chen, Yvonne E Lozano, Zerita White

Nicholas F Lyons's Documents

Publish Date Document Type Title
April, 2000 FDA 483 Response Abbott Laboratories - Form 483R, 2000-04-13
October, 2006 EIR Akorn, Inc. - EIR, 2006-10-10
April, 2000 FDA 483 Response Abbott Laboratories - Form 483R, 2000-08-28
April, 2001 EIR AbbVie Inc. - EIR, 2001-04-30
January, 2002 FDA 483 Response Organics LLC - Form 483R, 2002-02-11
March, 2002 EIR Woodstock Sterile Solutions, Inc - EIR, 2002-03-08
March, 2001 FDA 483 Response Morton Grove Pharmaceuticals, Inc. - Form 483R, 2001-03-23
October, 2000 EIR Regis Technologies Inc. - EIR, 2000-10-05
February, 2002 EIR Catalent Pharma Solutions, LLC - EIR, 2002-02-08
June, 2001 EIR ANDERSONBRECON INC. - EIR, 2001-06-21
August, 2001 EIR A-S Medication Solutions LLC - EIR, 2001-08-15
April, 2000 FDA 483 Abbott Laboratories - Form 483, 2000-03-31
March, 2000 FDA 483 Abbott Laboratories - Form 483, 2000-03-20
March, 2000 EIR Abbott Laboratories - EIR, 2000-03-20
January, 2002 EIR Organics LLC - EIR, 2002-01-18
April, 2000 EIR Abbott Laboratories - EIR, 2000-03-31
April, 2000 EIR Abbott Laboratories - EIR, 2000-04-10
January, 2002 FDA 483 Organics LLC - Form 483, 2002-01-18
April, 2001 FDA 483 Response AbbVie Inc. - Form 483R, 2001-05-18
August, 2001 FDA 483 A-S Medication Solutions LLC - Form 483, 2001-08-15
March, 2001 FDA 483 Morton Grove Pharmaceuticals, Inc. - Form 483, 2001-03-01
March, 2002 FDA 483 Novez Pharma - Form 483, 2002-03-28
April, 2001 FDA 483 AbbVie Inc. - Form 483, 2001-04-30
March, 2001 EIR Morton Grove Pharmaceuticals, Inc. - EIR, 2001-03-01
October, 2000 FDA 483 Regis Technologies Inc. - Form 483, 2000-10-05

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more